Načítá se...
Novel Therapies in Multiple Myeloma for Newly Diagnosed Non-Transplant Candidates
In the 21(st) Century, melphalan-prednisone can no longer be regarded as the standard treatment of multiple myeloma patients not eligible for high-dose melphalan followed by autologous stem cell transplantation. The introduction of thalidomide, lenalidomide and bortezomib has improved the arsenal of...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2009
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2818857/ https://ncbi.nlm.nih.gov/pubmed/20010166 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0b013e3181c60f08 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|